CordenPharma completes HPAPI laboratory expansion

Published: 19-Oct-2020
Manufacturing Finance Estates & Facilities

The laboratory is capable of handling highly potent compounds with an OEL as low as 1 ng/m3, and is already available to customers

CordenPharma has announced the completion of a highly potent API laboratory in its Boulder, Colorado facility.

CordenPharma says it has extensive experience and capabilities in the development and manufacturing of highly potent APIs from clinical to commercial scale. “Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand. This additional capacity benefits customers by expediting the onboarding of new projects,” said Jason Bertola, Director of CordenPharma’s Global Highly Potent & Oncology Platform.

  • Companies:
  • CordenPharma
See more

You may also like

Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

Read more
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase

Trending Articles

  1. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact they’re having on the pharmaceutical industry
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Adult vaccination programmes deliver significant socio-economic benefits, study finds The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Design & Build

CordenPharma expands early clinical peptide manufacturing offering

CordenPharma is pleased to announce the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers
Manufacturing

CordenPharma launches lipid nanoparticle starter kits

The kits will aid in loss mitigation of high-value payloads during the gene editing journey to market
Manufacturing

CPHI Barcelona Snapshot: CordenPharma

At CPHI Barcelona, Dr Kevin Robinson talked to Dr Michael Quirmbach, CEO and President of CordenPharma, about the company’s recent activities and what lies ahead
Manufacturing

CordenPharma increases peptide production capacity

Following the signature of a multi-year large scale peptide manufacturing agreement earlier this year, CordenPharma has announced the inauguration of increased commercial peptide production capacity with newly-upgraded facilities
Manufacturing

CordenPharma enters oligonucleotide manufacturing

With an organic capex investment in Two Phases, the strategic expansion will provide innovative biotech and pharma customers with a fully-integrated API to Drug Product service
Manufacturing

CordenPharma signs near USD $1bn manufacturing agreement

The companies have agreed not to disclose additional details and respect customer confidentiality
Subscribe now